Brief: Seres Therapeutics Announces Completion Of Patient Enrollment For SER-155 Phase 1B Cohort 2 Clinical Trial In Allogenic HSCT
09/04/2024 12:24
April 9 (Reuters) - Seres Therapeutics Inc MCRB.O :
* SERES THERAPEUTICS ANNOUNCES COMPLETION OF PATIENT
ENROLLMENT
FOR SER-155 PHASE 1B COHORT 2 CLINICAL TRIAL IN ALLOGENIC HSCT
* SERES THERAPEUTICS INC: CLINICAL DATA READOUT EXPECTED END
OF Q3
2024
Source text for Eikon: ID:nBw3VYzh9a
Further company coverage: MCRB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Seres Therapeutics
See all newsChinese automakers make tech-led pitch for Europe's premium car market
Brief: Seres Therapeutics - May Offer Up To $300 Million Of Securities
Seres Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Seres Therapeutics Q2 net income turns positive on VOWST sale gain
Brief: Seres Therapeutics Q2 EPS USD 0.47